ACC.24 sign American College of Cardiology

American College of Cardiology announces late-breaking clinical trials for ACC.25

The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.

George Dangas, MD, 2023-24 president of SCAI, director of cardiovascular innovation at Mount Sinai Hospital, and director of the TCT meeting, explains key trends he sees in interventional cardiology.

New directions and trends in interventional cardiology

Interventional cardiology continues to evolve, driven by rapid advancements in technology. George Dangas, MD, discussed some of the specialty's biggest ongoing trends with Cardiovascular Business. 

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

Valve durability after TAVR: Cardiologists track how deterioration influences outcomes

Researchers have made it a priority to learn as much about the durability of TAVR valves as possible. A new study in JACC: Cardiovascular Interventions used updated VARC-3 definitions to identify signs of hemodynamic valve deterioration in nearly 2,500 patients.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Early outcomes with Myval TAVR valve comparable to popular devices from Medtronic, Edwards

Meril Life Sciences has been manufacturing its Myval heart valves for years. The devices are approved and available in both India and Europe, but they have not been approved by the FDA.

STS President Jennifer C. Romano, MD, MS, a congenital heart surgeon with Mott Children’s Hospital and professor with the University of Michigan (UM) Medical School, spoke with Cardiovascular Business to preview STS 2025.

Q&A: Society of Thoracic Surgeons president previews the trends and technologies of STS 2025

It looked like the wildfires in Los Angeles could force STS to cancel its annual meeting, but the group worked with city officials and was able to carry on as planned. STS President Jennifer C. Romano, MD, MS, discussed that difficult decision and previewed the three-day event in a new interview.

Rakesh Gopinathannair, MD, FAHA, FACC, FHRS, director of cardiac electrophysiology laboratories at the Kansas City Heart Rhythm Institute, explains lessons from the AHA statement on COVID caused arrhythmias.

Key details associated with the treatment of COVID-induced arrhythmias

Rakesh Gopinathannair, MD, lead author of a recent American Heart Association scientific statement on cardiac arrhythmias associated with COVID-19, reviewed the latest science associated with this important topic.

Stephen Browning, FDA assistant director for hemodynamic and heart failure diagnostics, explains the FDA perspectives and regulatory pathways for AI-enabled cardiovascular devices at TCT 2024.

FDA regulator examines AI's growing influence in cardiology

Stephen Browning, the FDA's assistant director of hemodynamics and heart failure diagnostics, spoke with Cardiovascular Business about the agency's perspective on AI-enabled cardiovascular devices and many other topics.

Rebecca Hahn, MD, a principal investigator for the TRISCEND II trial, discusses key takeaways of the Edwards Lifesciences Evoque tricuspid TTVR valve.

Imaging specialist Rebecca Hahn explores key details about the Evoque TTVR device

Rebecca Hahn, MD, discussed key takeaways from the TRISCEND II trial for the Edwards Lifesciences Evoque TTVR valve and shared additional details related to patient selection and implanting the device.